Literature DB >> 29181824

AGEs-RAGE overexpression in a patient with smoking-related idiopathic nodular glomerulosclerosis.

Nao Nakamura1, Kensei Taguchi2, Yoshihiro Miyazono3, Keiichiro Uemura3, Kiyomi Koike4, Yuka Kurokawa1, Yosuke Nakayama1, Yusuke Kaida1, Ryo Shibata1, Akihiro Tsuchimoto5, Katsuhiko Asanuma6, Kei Fukami1.   

Abstract

We report a case of smoking-related idiopathic nodular glomerulosclerosis (ING) with overexpression of glomerular advanced glycation end products (AGEs) and their receptor (RAGE). A 59-year-old Japanese man with nephrotic syndrome, who had a smoking history of one pack of cigarettes per day for approximately 40 years, presented with a 3-year history of urinalysis abnormalities without clinical evidence of diabetic mellitus. The patient's leg edema progressively worsened over the previous 2 years, and he was admitted to our hospital. Renal biopsy showed mesangial expansion with diabetic Kimmelstiel-Wilson-like nodular lesions, glomerular basement thickening, and arteriosclerosis. No electron-dense deposits, fibrils, or microtubule deposits were seen in the glomeruli on electron microscopy. Skin AGE level measured using AGE reader was higher in this case than the average level in age-matched Caucasians. In addition, immunohistochemical analysis revealed that N-carboxymethyl lysine, one of the major AGEs, and RAGE were overexpressed and podocin expression was decreased in the peripheral area of the glomerular nodular lesions. These observations suggest that AGEs-RAGE system may be activated in smoking-related ING, possibly leading to the progression of renal dysfunction.

Entities:  

Keywords:  Advanced glycation end products; Cigarette smoking; Hypertension; Idiopathic nodular glomerulosclerosis; RAGE

Year:  2017        PMID: 29181824      PMCID: PMC5886922          DOI: 10.1007/s13730-017-0290-1

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  19 in total

1.  Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury.

Authors:  T Soulis; V Thallas; S Youssef; R E Gilbert; B G McWilliam; R P Murray-McIntosh; M E Cooper
Journal:  Diabetologia       Date:  1997-06       Impact factor: 10.122

Review 2.  Role of Advanced Glycation End Products and Its Receptors in the Pathogenesis of Cigarette Smoke-Induced Cardiovascular Disease.

Authors:  Kailash Prasad; Indu Dhar; Gudrun Caspar-Bell
Journal:  Int J Angiol       Date:  2015-06

3.  AGE-RAGE interaction and oxidative stress in obesity-related renal dysfunction.

Authors:  Yasuhiko Tomino; Shinji Hagiwara; Tomohito Gohda
Journal:  Kidney Int       Date:  2011-07       Impact factor: 10.612

4.  Serum soluble receptor for advanced glycation end products (sRAGE) is independently associated with cigarette smoking in non-diabetic healthy subjects.

Authors:  Subrata K Biswas; Sonchita R Mudi; Forhadul H Mollah; Angelika Bierhaus; M Iqbal Arslan
Journal:  Diab Vasc Dis Res       Date:  2013-03-21       Impact factor: 3.291

5.  Reference values of skin autofluorescence.

Authors:  M Koetsier; H L Lutgers; C de Jonge; T P Links; A J Smit; R Graaff
Journal:  Diabetes Technol Ther       Date:  2010-05       Impact factor: 6.118

6.  Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD.

Authors:  Lian Wu; Li Ma; Louise F B Nicholson; Peter N Black
Journal:  Respir Med       Date:  2010-11-26       Impact factor: 3.415

7.  Tobacco smoke is a source of toxic reactive glycation products.

Authors:  C Cerami; H Founds; I Nicholl; T Mitsuhashi; D Giordano; S Vanpatten; A Lee; Y Al-Abed; H Vlassara; R Bucala; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

Review 8.  Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis.

Authors:  Vivette D D'Agati; Avry Chagnac; Aiko P J de Vries; Moshe Levi; Esteban Porrini; Michal Herman-Edelstein; Manuel Praga
Journal:  Nat Rev Nephrol       Date:  2016-06-06       Impact factor: 28.314

9.  Telmisartan inhibits AGE-induced podocyte damage and detachment.

Authors:  Kei Fukami; Sho-ichi Yamagishi; Kumiko Kaifu; Takanori Matsui; Yusuke Kaida; Seiji Ueda; Masayoshi Takeuchi; Katsuhiko Asanuma; Seiya Okuda
Journal:  Microvasc Res       Date:  2013-05-03       Impact factor: 3.514

10.  The involvement of advanced glycation endproducts (AGEs) in renal injury of diabetic glomerulosclerosis: association with phenotypic change in renal cells and infiltration of immune cells.

Authors:  Yonghui Mao; Tetsuya Ootaka; Takao Saito; Hiroshi Sato; Toshinobu Sato; Sadayoshi Ito
Journal:  Clin Exp Nephrol       Date:  2003-09       Impact factor: 2.801

View more
  4 in total

1.  Nodular glomerulosclerosis in a kidney transplant recipient with impaired glucose tolerance: diabetic or idiopathic? A case report and literature review.

Authors:  Zhong Hong Liew; Puay Hoon Tan; Marjorie Foo; Terence Kee; Quan Yao Ho
Journal:  CEN Case Rep       Date:  2021-01-03

2.  Clinical, histopathologic and molecular features of idiopathic and diabetic nodular mesangial sclerosis in humans.

Authors:  Michael T Eadon; Sam Lampe; Mirza M Baig; Kimberly S Collins; Ricardo Melo Ferreira; Henry Mang; Ying-Hua Cheng; Daria Barwinska; Tarek M El-Achkar; Tae-Hwi Schwantes-An; Seth Winfree; Constance J Temm; Michael J Ferkowicz; Kenneth W Dunn; Katherine J Kelly; Timothy A Sutton; Sharon M Moe; Ranjani N Moorthi; Carrie L Phillips; Pierre C Dagher
Journal:  Nephrol Dial Transplant       Date:  2021-12-31       Impact factor: 5.992

3.  Pulmonary Function Tests and Their Associated Factors Among Type 2 Diabetic Patients at Jimma Medical Center, in 2019; Comparative Cross-Sectional Study.

Authors:  Dereje Gemeda Tesema; Teshome Gobena; Almaz Ayalew
Journal:  Int J Gen Med       Date:  2020-04-08

Review 4.  Dysbiosis-Related Advanced Glycation Endproducts and Trimethylamine N-Oxide in Chronic Kidney Disease.

Authors:  Kensei Taguchi; Kei Fukami; Bertha C Elias; Craig R Brooks
Journal:  Toxins (Basel)       Date:  2021-05-19       Impact factor: 4.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.